Literature DB >> 27637961

The epidemiology of amyotrophic lateral sclerosis.

E O Talbott1, A M Malek2, D Lacomis3.   

Abstract

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults and is characterized by neurodegeneration of motor neurons in the brain and spinal cord. The incidence of ALS is approximately 1-2.6 cases per 100 000 persons annually, whereas the prevalence is approximately 6 cases per 100 000. The average age of onset of ALS is currently 58-60 years and the average survival from onset to death is 3-4 years. Between October 19, 2010 and December 31, 2011, there were an estimated 12 187 prevalent cases diagnosed with definite ALS in the USA alone. Sporadic ALS (90-95%) constitutes the large majority of cases, while the remaining 5-10% are hereditary and termed familial ALS. Sporadic ALS is suspected to involve genetic susceptibility to environmental risk factors. The purpose of this review is to present a clinical overview of ALS and provide an epidemiologic summary of personal and environmental risk factors shown to be related to the risk of disease. A discussion of the most recent research initiatives is also included.
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  amyotrophic lateral sclerosis; epidemiology; motor neuron disease; neurodegenerative; risk factor

Mesh:

Year:  2016        PMID: 27637961     DOI: 10.1016/B978-0-12-802973-2.00013-6

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  69 in total

1.  Epidemiology of paraneoplastic neurological syndromes: a population-based study.

Authors:  Alberto Vogrig; Gian Luigi Gigli; Samantha Segatti; Elisa Corazza; Alessandro Marini; Andrea Bernardini; Francesca Valent; Martina Fabris; Francesco Curcio; Francesco Brigo; Donatella Iacono; Paolo Passadore; Michele Rana; Jérôme Honnorat; Mariarosaria Valente
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

Review 2.  Targeting the "hallmarks of aging" to slow aging and treat age-related disease: fact or fiction?

Authors:  Maryam Keshavarz; Kan Xie; Kristina Schaaf; Daniele Bano; Dan Ehninger
Journal:  Mol Psychiatry       Date:  2022-07-15       Impact factor: 13.437

Review 3.  Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.

Authors:  Flavien Bizot; Adeline Vulin; Aurélie Goyenvalle
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

4.  The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice.

Authors:  Diane Ly; Anjila Dongol; Peter Cuthbertson; Thomas V Guy; Nicholas J Geraghty; Reece A Sophocleous; Lucia Sin; Bradley J Turner; Debbie Watson; Justin J Yerbury; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2020-03-13       Impact factor: 3.765

Review 5.  Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.

Authors:  Ruth Chia; Adriano Chiò; Bryan J Traynor
Journal:  Lancet Neurol       Date:  2017-11-16       Impact factor: 44.182

Review 6.  Proteostatic imbalance and protein spreading in amyotrophic lateral sclerosis.

Authors:  Maria Elena Cicardi; Lara Marrone; Mimoun Azzouz; Davide Trotti
Journal:  EMBO J       Date:  2021-03-31       Impact factor: 11.598

Review 7.  Microglial TREM2 in amyotrophic lateral sclerosis.

Authors:  Manling Xie; Shunyi Zhao; Dale B Bosco; Aivi Nguyen; Long-Jun Wu
Journal:  Dev Neurobiol       Date:  2021-12-18       Impact factor: 3.964

Review 8.  Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date.

Authors:  Ivana Štětkářová; Edvard Ehler
Journal:  Diagnostics (Basel)       Date:  2021-02-03

Review 9.  The effects of diet and sex in amyotrophic lateral sclerosis.

Authors:  J A Pape; J H Grose
Journal:  Rev Neurol (Paris)       Date:  2020-03-05       Impact factor: 2.607

10.  Free energy calculations of ALS-causing SOD1 mutants reveal common perturbations to stability and dynamics along the maturation pathway.

Authors:  Nicholas G M Wells; Grant A Tillinghast; Alison L O'Neil; Colin A Smith
Journal:  Protein Sci       Date:  2021-06-22       Impact factor: 6.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.